1. Delmas PD (2008) Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases. J Clin Densitom 11:325–338
2. U.S. Food and Drug Administration (2010) Press announcements: FDA approves new injectable osteoporosis treatment for postmenopausal women. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm214150.htm Accessed 02 Jan 2017
3. European Medicines Agency (2010) Prolia. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001120/human_med_001324.jsp&mid=WC0b01ac058001d124 . Accessed 02 Jan 2017
4. U.S. Food and Drug Administration (2010) Press announcements: FDA approves Xgeva to help prevent cancer-related bone injury. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm234346.htm Accessed 02 Jan 2017
5. European Medicines Agency (2011) Xgeva. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002173/human_med_001463.jsp&mid=WC0b01ac058001d124 . Accessed 02 Jan 2017